The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; none of the 27 sources its claims cite is checked for support yet.
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Open accessAbstract
Summary Background A severe form of encephalitis associated with antibodies against NR1–NR2 heteromers of the NMDA receptor was recently identified. We aimed to analyse the clinical and immunological features of patients with the disorder and examine the effects of antibodies against NMDA receptors in neuronal cultures. Methods We describe the clinical characteristics of 100 patients with encephalitis and NR1–NR2 antibodies. HEK293 cells ectopically expressing single or assembled NR1–NR2 subunits were used to determine the epitope targeted by the antibodies. Antibody titres were measured with ELISA. The effect of antibodies on neuronal cultures was determined by quantitative analysis of NMDA-receptor clusters. Findings Median age of patients was 23 years (range 5–76 years); 91 were women. All patients presented with psychiatric symptoms or memory problems; 76 had seizures, 88 unresponsiveness (decreased conciousness), 86 dyskinesias, 69 autonomic instability, and 66 hypoventilation. 58 (59%) of 98 patients for whom results of oncological assessments were available had tumours, most commonly ovarian teratoma. Patients who received early tumour treatment (usually with immunotherapy) had better outcome (p=0.004) and fewer neurological relapses (p=0.009) than the rest of the patients. 75 patients recovered or had mild deficits and 25 had severe deficits or died. Improvement was associated with a decrease of serum antibody titres. The main epitope targeted by the antibodies is in the extracellular N-terminal domain of the NR1 subunit. Patients’ antibodies decreased the numbers of cell-surface NMDA receptors and NMDA-receptor clusters in postsynaptic dendrites, an effect that could be reversed by antibody removal. Interpretation A well-defined set of clinical characteristics are associated with anti-NMDA-receptor encephalitis. The pathogenesis of the disorder seems to be mediated by antibodies.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This case series characterizes 100 patients with anti-NMDA-receptor encephalitis and shows that antibodies target the extracellular N-terminal domain of NR1, reduce cell-surface NMDA receptors and postsynaptic receptor clusters, and that early tumour treatment is associated with better outcome and fewer relapses. The disorder is severe but often reversible, with 75 patients recovering or having mild deficits and 25 having severe deficits or dying.
Key findings
- Among 100 patients, median age was 23 years (range 5–76) and 91 were women; all presented with psychiatric symptoms or memory problems, 76 had seizures, 88 unresponsiveness, 86 dyskinesias, 69 autonomic instability, and 66 hypoventilation.
- 58 (59%) of 98 assessed patients had tumours, most commonly ovarian teratoma; early tumour treatment was associated with better outcome (p=0.004) and fewer neurological relapses (p=0.009) than in other patients.
- 75 patients recovered or had mild deficits and 25 had severe deficits or died; improvement was associated with a decrease in serum antibody titres.
- Patients’ antibodies mainly targeted the extracellular N-terminal domain of NR1 and decreased cell-surface NMDA receptors and NMDA-receptor clusters in postsynaptic dendrites, an effect reversed by antibody removal.
Methods
- Observational case series of 100 patients with encephalitis and NR1–NR2 antibodies; clinical information was obtained by authors or referring physicians, with control samples from 20 healthy individuals and 230 patients with suspected autoimmune or paraneoplastic encephalitis or tumours without encephalitis.
- HEK293 cells expressing single or assembled NR1–NR2 subunits were used to map the antibody epitope; antibody titres were measured by ELISA, and effects on neuronal cultures were assessed by quantitative confocal analysis of NMDA-receptor clusters and by biotinylation/immunoblot of cell-surface NR1.
- Statistical analyses used Fisher’s two-sided exact test, Kruskal-Wallis and Wilcoxon rank-sum tests with Bonferroni correction, and Kruskal-Wallis non-parametric ANOVA with Dunn’s pairwise comparison.
Limitations
- The paper states that follow-up CSF titres were not obtained in most patients after improvement, and that future studies should clarify the best type and duration of immunotherapy, the role of prodromal events, and the molecular mechanisms decreasing NMDA receptors.
- Evident from the text: this is an observational case series without randomized treatment allocation, so associations between early tumour treatment and outcome may be confounded; some clinical and laboratory data are reported as “data not shown.”
- Evident from the text: the pathogenic evidence relies partly on in-vitro rat hippocampal neuronal cultures and HEK293 assays, which may not fully capture human disease mechanisms.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
70 Own result · 15 Not checked yet · 13 Own interpretation · 1 Own method
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All patients presented with psychiatric symptoms or memory problems; 76 had seizures, 88 unresponsiveness (decreased conciousness), 86 dyskinesias, 69 autonomic instability, and 66 hypoventilation.”
- Also stated in: § Results · plain
“During the first 3 weeks of symptom presentation, 76 patients had seizures.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Abstract > Findings
plainn = 76- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Median age of patients was 23 years (range 5–76 years); 91 were women.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Abstract > Findings
plainn = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Median age of patients was 23 years (range 5–76 years); 91 were women.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Abstract > Findings
plainn = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All patients presented with psychiatric symptoms or memory problems; 76 had seizures, 88 unresponsiveness (decreased conciousness), 86 dyskinesias, 69 autonomic instability, and 66 hypoventilation.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Abstract > Findings
plainn = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“92 patients had extensive EEG monitoring, 77% had generalised or predominantly frontotemporal slow or disorganised activity (delta-theta) without epileptic discharges.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 92- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“20 (27%) had prominent sleep dysfunction, including hypersomnia and inversion of sleep patterns.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 75- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“23 presented with short-term memory loss or seizures alone or associated with psychiatric manifestations.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plaincorrelationaln = 23- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of hospitalisation was 2.5 months (range 1–14 months).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In six patients, the tumour was diagnosed after recovery from the encephalitis (56–380 months).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The main epitope targeted by the antibodies is in the extracellular N-terminal domain of the NR1 subunit.”
- Also stated in: § Results · plain
“Hence the main epitope region recognised by all patients’ antibodies lies within the extracellular region of the NR1 subunit (webtable 3).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Abstract > Findings
plainn = 92- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
- It may state two separate claims as one. 30
- Probably not a substantial claim. 8
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One boy (11 years old, without tumour) and 21 women and girls were younger than 19 years (median 15 years, range 5–18 years); 12 had an ovarian teratoma (five with immature features), and nine had no tumour.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 21- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“14 patients had brain biopsy: findings for two were normal, 12 showed mild perivascular lymphocytic cuffng, and ten microglial activation.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 14- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time from symptom presentation to initial signs of improvement was 8 weeks (range 2–24 weeks) for the group of patients with early tumour treatment, 11 weeks (4–40 weeks) for the group whose tumour was treated late or not treated, and 10 weeks (2–50 weeks) for the group without tumour (Kruskal-Wallis, p=0.10)”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All had negative results for neuronophagic nodules and viral assays.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 14- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“37 patients had cardiac dysrhythmias, including tachycardia or bradycardia, with prolonged pauses in seven patients; four needed pacemakers.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 37- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While hospitalised, seven patients had high levels of serum creatine kinase, six developed pulmonary embolism, six transient aphasia, four hemiparesis, and four tetraparesis.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Median follow-up was 17 months (1–194 months): 47 patients had full recovery, 28 mild stable deficits, 18 severe deficits, and seven died as a result of the neurological disorder.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 47- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“52 patients had dyskinesias, autonomic instability, and hypoventilation, 27 patients had two of these symptoms, and 14 had just one; the remaining seven patients developed a milder syndrome of seizures and psychiatric symptoms.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 52- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All teratomas contained nervous tissue; 25 were examined for expression of NMDA receptors, and all were positive (data not shown).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Eight patients had bilateral teratomas; four were synchronous, two had history of a contralateral teratoma, and two developed contralateral teratomas before recurrence of the encephalitis.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 8- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings were limited to a single area of the brain in 19 patients: 16 had abnormalities in medial temporal lobes, two in the corpus callosum, and one in the brainstem.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 19- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients who improved had a parallel decrease of serum titres, whereas those who did not improve maintained high titres in CSF and serum (figure 3).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Relapses were less common in patients with early tumour treatment (1 of 36) than in other patients (14 of 64; p=0.009), including patients whose tumour was treated late (six of 22; p=0.009) and patients without tumour (eight of 42; p=0.03).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our study indicates that 41% of patients with anti-NMDA-receptor encephalitis do not have a clinically detectable tumour, and that men and children can also be affected.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Four patients who died and whose CSF was available were among the group with the highest titres, whereas the seven patients with milder syndromes had the lowest titres (data not shown).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plaincorrelationaln = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The use of these heteromers abrogated the reactivity of sera or CSF from 92 patients’, and substantially decreased the reactivity of the samples of the remaining eight cases.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plaindirectn = 92- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While poorly responsive or in a catatonic-like state, 93 patients developed hypoventilation, autonomic imbalance, or abnormal movements, all overlapping in 52 patients.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
plaincorrelationaln = 93- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Analysis of the reactivity of patients’ sera or CSF against the indicated NMDA-receptor subunits or heteromers showed that antibody reactivity was not modified by changing the NR2 subunit (A, B, C, or D) and was retained by homomers of NR1 (webtable 3).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The receptors are heteromers of NR1 subunits that bind glycine and NR2 (A, B, C, or D) subunits that bind glutamate.1”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [1] Lynch, 1994, N-methyl-D-aspartate receptors: different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents, Mol Pharmacol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Preliminary studies suggested the target epitopes were located in extracellular regions of NR1–NR2B NMDA receptors.5”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [5] Dalmau, 2007, Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma, Ann Neurol source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Despite the severity of the disorder, patients often recovered after tumour removal and immunotherapy, suggesting an immune-mediated pathogenesis.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [5] Dalmau, 2007, Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma, Ann Neurol source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“NMDA receptors are ligand-gated cation channels with crucial roles in synaptic transmission and plasticity.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [1] Lynch, 1994, N-methyl-D-aspartate receptors: different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents, Mol Pharmacol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All patients had brain MRI, radiological screening for a systemic neoplasm, and serological or CSF studies that ruled out other disorders (webappendix).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Methods > Patients and procedures
plainn = 21- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [2] Coyle, 2006, Glutamate and schizophrenia: beyond the dopamine hypothesis, Cell Mol Neurobiol source
- Not checked yetcites [3] Waxman, 2005, N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease, Neuroscientist source
- Not checked yetcites [4] Lau, 2007, NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders, Nat Rev Neurosci source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Serum and CSF were tested for antibodies against the NMDA receptor,5 and considered positive if three immunohistochemical criteria were fulfilled (figure 1).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Methods > Patients and procedures
What the sources say
- Not checked yetcites [5] Dalmau, 2007, Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma, Ann Neurol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [2] Coyle, 2006, Glutamate and schizophrenia: beyond the dopamine hypothesis, Cell Mol Neurobiol source
- Not checked yetcites [3] Waxman, 2005, N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease, Neuroscientist source
- Not checked yetcites [4] Lau, 2007, NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders, Nat Rev Neurosci source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The first patients identified were young women with ovarian teratoma who presented with psychosis or memory problems, rapidly progressing to multiple neurological deficits requiring prolonged intensive care support.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [5] Dalmau, 2007, Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma, Ann Neurol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“We recently identified a disorder, designated anti-NMDA-receptor encephalitis, that associates with antibodies against NR1–NR2 heteromers and results in a characteristic neuropsychiatric syndrome.5”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [5] Dalmau, 2007, Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma, Ann Neurol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Neurological outcome was assessed with the modified Rankin scale (MRS)10 and mini-mental state examination (MMSE).11”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Methods > Patients and procedures
What the sources say
- Not checked yetcites [10] van Swieten, 1988, Interobserver agreement for the assessment of handicap in stroke patients, Stroke source
- Not checked yetcites [11] Folstein, 1975, “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The latter effect was reversed by removing the antibodies from the cultures, explaining the potential reversibility of patients’ symptoms.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Anti-NMDA-receptor encephalitis represents a new category of immune-mediated disorder that is often paraneoplastic, treatable, and can be diagnosed serologically.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, although the presence of a tumour that expresses NMDA receptors likely contributes to breaking immune tolerance, other unknown immunological triggers seem to be involved.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Recovery from this disorder is typically slow, and symptoms may relapse, especially in patients with undetected or recurrent tumours and patients with no associated tumours.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A pathogenic role of patients’ antibodies is suggested by the correlation between antibody titres and neurological outcome and by the decrease in number of postsynaptic clusters of NMDA receptors caused by patients’ antibodies.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The effects of patients’ antibodies on rat hippocampal neuronal cultures reflect the effects of those antibodies on human neurons in anti-NMDA-receptor encephalitis.
“To assess the effect of patients’ antibodies on neuronal cultures, we first determined the extent of immunolabelling of NR1 (or NMDA receptor) clusters in postsynaptic dendrites.”
The paper relies on this without support.
HEK293 cells ectopically expressing recombinant NR1 or NR1–NR2B subunits present the same epitopes as native NMDA receptors for patients’ antibodies.
“Antibody titres were measured with ELISA on HEK293 cell lysates ectopically expressing NR1 or NR1–NR2B heteromers (webappendix).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psychotomimetic models (eg, models that mimic the symptoms of psychosis), especially those based on ketamine (an antagonistic agent of NMDA-R), also support the E/I imbalance hypothesis.”
From Are hallucinations due to an imbalance between excitatory and inhibitory influences on the brain? (2016) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients usually present with acute behavioral change, psychosis and catatonia that evolve to include seizures, memory deficit, dyskinesias, speech problems, and autonomic and breathing dysregulation.3”
From Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study (2013) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“If a tumor is found, removal is important because it expedites improvement and decreases relapses.3, 17”
From Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study (2013) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Samples were considered positive if they fulfilled previously reported criteria3 including (1) a characteristic pattern of immunostaining of the neuropil of rat brain, and (2) specific reactivity with HEK293 cells expressing GluN1 (also known as NR1) subunits of the NMDAR.”
From Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study (2013) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The disorder, named “anti-NMDAR encephalitis”, has since been recognized in patients of all ages, but more frequently in young adults and children with or without teratoma.3, 4”
From Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study (2013) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Despite the severity of the disease, patients often improve after intensive care support, immunotherapy, and prolonged hospitalizations that require multidisciplinary care.3, 11”
From Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study (2013) · cites this paper as [3]
In the citing paper
“Recently, autoimmune diseases associated with anti-NMDAR antibodies were reported to be associated with severe psychosis 14 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
“All but one of these patients developed neurological symptoms before the tumour diagnosis (median 8 weeks, range 1–380 weeks).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
“In six patients, the tumour was diagnosed after recovery from the encephalitis (56–380 months).”
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Paraneoplastic anti– N ‐methyl‐ D ‐aspartate receptor encephalitis associated with ovarian teratoma
Dalmau, J., Tüzün, E., Wu, H., Masjuan, J., Rossi, J. E., Voloschin, A., Baehring, J. M., Shimazaki, H., Koide, R., King, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21050 · Cited by 2,492
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders
Lau, C. G., & Zukin, R. S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2153 · Cited by 1,159
Tibbling, G., Link, H., & Ohman, S. (1977) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365517709091496 · Cited by 971
Cited by
Sorted by citations
Items 301–400 of 1,002
Wegner, F., Wilke, F., Raab, P., Tayeb, S. B., Boeck, A.-L., Haense, C., Trebst, C., Voß, E. V., Schrader, C., Logemann, F., et al. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-136 · Cited by 91
Endres, D., Meixensberger, S., Dersch, R. S., Feige, B., Stich, O., Venhoff, N., Matysik, M., Maier, S. J., Michel, M., Runge, K., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00967-3 · Cited by 90
Rege, S., & Hodgkinson, S. J. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413499077 · Cited by 90
Benarroch, E. E. (2011) · Neurology · doi:10.1212/wnl.0b013e31821b7cc9 · Cited by 90
Zerche, M., Weißenborn, K., Ott, C., Dere, E., Asif, A. R., Worthmann, H., Hassouna, I. A., Rentzsch, K., Tryc, A. B., Dahm, L., et al. (2015) · Stroke · doi:10.1161/strokeaha.114.008323 · Cited by 90
Geller, D. A., Homayoun, S., & Johnson, G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.678538 · Cited by 89
The recognition and treatment of autoimmune epilepsy in children
Suleiman, J., & Dale, R. C. (2014) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12647 · Cited by 89
Castillo‐Gomez, E., Kästner, A., Steiner, J., Schneider, A., Hettling, B., Poggi, G., Ostehr, K., Uhr, M., Asif, A. R., Matzke, M., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24545 · Cited by 89
Liu, C., Zhu, J., Zheng, X., Ma, C., & Wang, X. (2017) · Mediators of Inflammation · doi:10.1155/2017/6361479 · Cited by 89
Predictive value of electroencephalography in anti-NMDA receptor encephalitis
van Sonderen, A., Arends, S., Tavy, D. L. J., Bastiaansen, A. E. M., de Bruijn, M. A. A. M., Schreurs, M. W. J., Smitt, P. A. E. S., & Titulaer, M. J. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318376 · Cited by 89
Neurologic complications in herpes simplex encephalitis: clinical, immunological and genetic studies
Armangué, T., Olivé-Cirera, G., Martínez‐Hernández, E., Rodés, M., Sempere, V. P., Guasp, M., Ruiz‐García, R., Palou, E., González, A., Marcos, M. Á., et al. (2023) · Brain · doi:10.1093/brain/awad238 · Cited by 89
Self-citationConsoli, A., Raffin, M., Laurent‐Levinson, C., Bodeau, N., Campion, D., Amoura, Z., Sedel, F., Gourfinkel‐An, I., Bonnot, O., & Cohen, D. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.012 · Cited by 89
Anti–N-methyl-D-aspartate Receptor Encephalitis During Pregnancy
Kumar, M. A., Jain, A., Dechant, V. E., Saito, T., Rafael, T. J., Aizawa, H., Dysart, K., Katayama, T., Ito, Y., Araki, N., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.133 · Cited by 89
Self-citationAntibody-Mediated Autoimmune Encephalopathies and Immunotherapies
Gastaldi, M., Thouin, A., & Vincent, A. C. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0410-6 · Cited by 88
Plasma exchange in pediatric anti-NMDAR encephalitis: A systematic review
Suppiej, A., Nosadini, M., Zuliani, L., Pelizza, M. F., Toldo, I., Bertossi, C., Tison, T., Zoccarato, M., Marson, P., Giometto, B., et al. (2016) · Brain and Development · doi:10.1016/j.braindev.2016.01.009 · Cited by 88
Burden of herpes simplex virus encephalitis in the United States
Modi, S., Mahajan, A., Dharaiya, D., Varelas, P., & Mitsias, P. D. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8516-x · Cited by 88
Patient characteristics and outcome associations in AMPA receptor encephalitis
Laurido-Soto, O., Brier, M. R., Simon, L. E., McCullough, A. A., Bucelli, R. C., & Day, G. S. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9153-8 · Cited by 91
Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges
Mann, A. P., Lukas, R. V., & Grebenciucova, E. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s61967 · Cited by 87
Byun, J., Lee, S., Jung, K., Sunwoo, J., Moon, J., Lim, J., Lee, D. Y., Shin, Y., Kim, T., Lee, K., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146455 · Cited by 87
Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF
Carta, S., Cobo‐Calvo, Á., Armangué, T., Saiz, A., Lechner, C., Rostasy, K. M., Breu, M., Baumann, M., Höftberger, R., Ayzenberg, I., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201662 · Cited by 91
Davies, G. R., Irani, S. R., Coltart, C. E. M., Ingle, G. T., Amin, Y., Taylor, C., Radcliffe, J. J., Hirsch, N. P., Howard, R., Vincent, A. C., et al. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181cb0968 · Cited by 86
Autoimmune Encephalitis and Its Relation to Infection
Venkatesan, A., & Benavides, D. R. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0529-1 · Cited by 86
Leypoldt, F., Wandinger, K.-P., Bien, C. G., & Dalmau, J. O. (2012) · European Neurological Review · doi:10.17925/enr.2013.08.01.31 · Cited by 86
Self-citationAutoimmune Encephalitis Resembling Dementia Syndromes
Bastiaansen, A. E. M., van Steenhoven, R. W., de Bruijn, M. A. A. M., Crijnen, Y. S., van Sonderen, A., van Coevorden‐Hameete, M. H., Nühn, M. M., Verbeek, M. M., Schreurs, M. W. J., Smitt, P. A. E. S., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001039 · Cited by 85
Vincent, A. C., & Bien, C. G. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70225-4 · Cited by 85
Ovarian Teratoma Associated With Anti-N-Methyl D-Aspartate Receptor Encephalitis
Dabner, M., McCluggage, W. G., Bundell, C., Carr, A. S., Leung, Y. C., Sharma, R. N., & Stewart, C. J. R. (2012) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31824a1de2 · Cited by 84
Hernandez, A. R., Simorowski, N., Karakaş, E., & Furukawa, H. (2016) · Neuron · doi:10.1016/j.neuron.2016.11.006 · Cited by 84
Wesselingh, R., Butzkueven, H., Buzzard, K., Tarlinton, D., O'Brien, T. J., & Monif, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02066 · Cited by 83
Brickshawana, A., Hinson, S. R., Romero, M. F., Lucchinetti, C. F., Guo, Y. X., Buttmann, M., McKeon, A. B., Pittock, S. J., Chang, M.-H., Chen, A., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70141-3 · Cited by 83
CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG
McKeon, A. B., Pittock, S. J., & Lennon, V. A. (2011) · Neurology · doi:10.1212/wnl.0b013e318211c379 · Cited by 83
Antibody Repertoire in Paraneoplastic Cerebellar Degeneration and Small Cell Lung Cancer
Sabater, L., Höftberger, R., Boronat, A., Saiz, A., Dalmau, J. O., & Graus, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060438 · Cited by 83
Self-citationDeSena, A. D., Noland, D. K., Matevosyan, K., King, K., Phillips, L. T., Qureshi, S. S., Greenberg, B. M., & Graves, D. F. (2015) · Journal of Clinical Apheresis · doi:10.1002/jca.21363 · Cited by 83
HLA class II alleleDRB1*16:02is associated with anti-NMDAR encephalitis
Shu, Y., Qiu, W., Zheng, J., Sun, X., Yin, J., Yang, X., Yue, X., Chen, C., Deng, Z., Li, S., et al. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-319714 · Cited by 83
Neural antigen‐specific autoimmune disorders
Iorio, R., & Lennon, V. A. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01144.x · Cited by 82
Diagnosis and treatment of rapidly progressive dementias
Paterson, R. W., Takada, L. T., & Geschwind, M. D. (2012) · Neurology Clinical Practice · doi:10.1212/cpj.0b013e31826b2ae8 · Cited by 82
EEG analysis in anti-NMDA receptor encephalitis: Description of typical patterns
Jeannin-Mayer, S., André‐Obadia, N., Rosenberg, S. D., Boutet, C., Honnorat, J., Antoine, J.-C. G., & Mazzola, L. (2018) · Clinical Neurophysiology · doi:10.1016/j.clinph.2018.10.017 · Cited by 82
Inflammation, ictogenesis, and epileptogenesis: An exploration through human disease
Tan, T., Perucca, P., O'Brien, T. J., Kwan, P., & Monif, M. (2020) · Epilepsia · doi:10.1111/epi.16788 · Cited by 82
Blood–Brain Barrier Disruption in Neuroimmunological Disease
Shimizu, F., & Nakamori, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910625 · Cited by 88
Dhossche, D. M., Stoppelbein, L., & Rout, U. K. (2010) · Journal of Ect · doi:10.1097/yct.0b013e3181fbf96d · Cited by 82
Antibody-Mediated Autoimmune Encephalitis in Childhood
Brenton, J. N., & Goodkin, H. P. (2016) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2016.04.004 · Cited by 82
Saint‐Martin, M., Joubert, B., Pellier‐Monnin, V., Pascual, O., Noraz, N., & Honnorat, J. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14081 · Cited by 91
Newman, M., Blum, S., Wong, R. C. W., Scott, J. G., Prain, K. M., Wilson, R. J., & Gillis, D. (2016) · Internal Medicine Journal · doi:10.1111/imj.12974 · Cited by 81
Birbas, E., Kanavos, T., Gkrozou, F., Skentou, C., Daniilidis, A., & Vatopoulou, A. (2023) · Children · doi:10.3390/children10071114 · Cited by 81
Mimics of Autoimmune Encephalitis
van Steenhoven, R. W., de Vries, J. M., Bruijstens, A. L., Paunovic, M., Nagtzaam, M. M. P., Franken, S. C., Bastiaansen, A. E. M., de Bruijn, M. A. A. M., van Sonderen, A., Schreurs, M. W. J., et al. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200148 · Cited by 81
Antibodies to the N-Methyl-D-Aspartate Receptor and Other Synaptic Proteins in Psychosis
Deakin, J., Lennox, B., & Zandi, M. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.018 · Cited by 81
Holtkamp, M., & Meierkord, H. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611403826 · Cited by 83
Neurobehavioral outcomes in autoimmune encephalitis
Yeshokumar, A. K., Gordon‐Lipkin, E. M., Arenivas, A., Cohen, J., Venkatesan, A., Saylor, D. R., & Probasco, J. C. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.08.010 · Cited by 81
Busse, S., Busse, M., Brix, B., Probst, C., Genz, A., Bogerts, B., Stoecker, W., & Steiner, J. H. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0493-9 · Cited by 80
Catatonia in patients with anti‐NMDA receptor encephalitis
Espínola-Nadurille, M., Flores-Rivera, J. D. J., Rivas‐Alonso, V., Vargas‐Cañas, S., Fricchione, G. L., Bayliss, L., Martínez-Juárez, I. E., Hernández‐Vanegas, L. E., Martinez‐Hernandez, R., Bautista‐Gomez, P., et al. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12867 · Cited by 80
Stein, H., Barbosa, J., Rosa-Justícia, M., Prades, L., Morató, A., Galan-Gadea, A., Ariño, H., Martínez‐Hernández, E., Castro‐Fornieles, J., Dalmau, J. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18033-3 · Cited by 80
Self-citationParaneoplastic neurologic syndrome: A practical approach
Kannoth, S. (2012) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.93267 · Cited by 80
The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesis
Ramanathan, S., Al‐Diwani, A., Waters, P. J., & Irani, S. R. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09590-9 · Cited by 80
Zhang, L., Wu, M., Hao, Z., Chiang, S. M. V., Shuang, K., Lin, M., Chi, X., Fang, J., Zhou, D., & Li, J. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.12.019 · Cited by 79
Zuliani, L., Nosadini, M., Gastaldi, M., Spatola, M., Iorio, R., Zoccarato, M., Mariotto, S., Gaspari, P. D., Perini, F., Ferrari, S., et al. (2019) · Neurological Sciences · doi:10.1007/s10072-019-03930-3 · Cited by 79
Sleep disorders in anti-NMDAR encephalitis
Ariño, H., Lopetegi, A. M., Martínez‐Hernández, E., Armangué, T., Rosa-Justícia, M., Escudero, D., Matos, N., Graus, F., Sugranyes, G., Castro‐Fornieles, J., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009987 · Cited by 83
Self-citationPearlman, D. M., Vora, H. S., Marquis, B. G., Najjar, S., & Dudley, L. (2014) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.137018 · Cited by 81
Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System
Pilli, D., Zou, A., Tea, F., Dale, R. C., & Brilot, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00652 · Cited by 81
Mannara, F., Radosevic, M., Planagumà, J., Soto, D., Aguilar, E., García‐Serra, A., Maudes, E., Pedreño, M., Paul, S. M., Doherty, J., et al. (2020) · Brain · doi:10.1093/brain/awaa195 · Cited by 78
Self-citationA prospective study of acute movement disorders in children
Dale, R. C., SINGH, H., Troedson, C., Pillai, S. C., GAIKIWARI, S., & Kozlowska, K. (2010) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2009.03598.x · Cited by 78
Investigation of neuronal autoantibodies in two different focal epilepsy syndromes
Ekizoğlu, E., Tüzün, E., Woodhall, M. R., Lang, B., Jacobson, L. W., İçöz, S., Bebek, N., Gürses, C., Gökyiğit, A., Waters, P. J., et al. (2014) · Epilepsia · doi:10.1111/epi.12528 · Cited by 78
Luca, N. J. C., Daengsuwan, T., Dalmau, J. O., Jones, K., deVeber, G., Kobayashi, J. S., Laxer, R. M., & Benseler, S. M. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30437 · Cited by 78
Self-citationQin, K., Wu, W., Huang, Y., Xu, D., Zhang, L., Zheng, B., Jiang, M., Kou, C., Gao, J., Li, W., et al. (2017) · BMC Neurology · doi:10.1186/s12883-016-0787-9 · Cited by 78
Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis
Budhram, A., Dubey, D., Sechi, E., Flanagan, E. P., Yang, L., Bhayana, V., McKeon, A. B., Pittock, S. J., & Mills, J. R. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa254 · Cited by 78
Neuropathological Variability within a Spectrum of NMDAR ‐Encephalitis
Zrzavy, T., Endmayr, V., Bauer, J., Macher, S., Mossaheb, N., Schwaiger, C., Ricken, G., Winklehner, M., Glatter, S., Breu, M., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26223 · Cited by 77
Self-citationTurner, S. J., Mayes, A., Verhoeven, A., Mandelstam, S. A., Morgan, A. T., & Scheffer, I. E. (2015) · Neurology · doi:10.1212/wnl.0000000000001228 · Cited by 77
Kirkpatrick, M. P., Clarke, C. D., Sonmezturk, H. H., & Abou-Khalil, B. W. (2010) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2010.11.020 · Cited by 77
Late onset autism and anti-NMDA-receptor encephalitis
Creten, C., van der Zwaan, S., Blankespoor, R. J., Maatkamp, A., Nicolai, J., van Os, J., & Schieveld, J. N. M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60548-5 · Cited by 77
Paraneoplastic neuronal intermediate filament autoimmunity
Basal, E., Zalewski, N. L., Kryzer, T. J., Hinson, S. R., Guo, Y. X., Dubey, D., Benarroch, E. E., Lucchinetti, C. F., Pittock, S. J., Lennon, V. A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006435 · Cited by 77
Garg, N., Reddel, S. W., Miller, D. H., Chataway, J., Riminton, D. S., Barnett, Y., Masters, L., Barnett, M. H., & Hardy, T. A. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309649 · Cited by 76
Autoimmune Encephalitis: Current Knowledge on Subtypes, Disease Mechanisms and Treatment
Nissen, M. S., Ryding, M., Meyer, M., & Blaabjerg, M. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200708133103 · Cited by 76
Bastiaansen, A. E. M., de Bruijn, M. A. A. M., Schuller, S. L., Martínez‐Hernández, E., Brenner, J., Paunovic, M., Crijnen, Y. S., Mulder, M. J. H. L., Schreurs, M. W. J., de Graaff, E., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001127 · Cited by 76
Autoimmune and inflammatory mechanisms of CNS damage
Kapadia, M., & Šakić, B. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.008 · Cited by 75
Anti–NMDA Receptor Encephalitis
Jones, K., Benseler, S. M., & Moharir, M. D. (2013) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2012.12.009 · Cited by 75
Paraneoplastic Disorders of the CNS and Autoimmune Synaptic Encephalitis
Rosenfeld, M. R., & Dalmau, J. O. (2012) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000413664.42798.aa · Cited by 75
Self-citationNew drug developments in psychosis: Challenges, opportunities and strategies
Keshavan, M. S., Lawler, A. N., Nasrallah, H. A., & Tandon, R. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.07.004 · Cited by 79
Seizure specificities in patients with antibody‐mediated autoimmune encephalitis
Vogrig, A., Joubert, B., André‐Obadia, N., Gigli, G. L., Rheims, S., & Honnorat, J. (2019) · Epilepsia · doi:10.1111/epi.16282 · Cited by 75
The spectrum of CNS vasculitis in children and adults
Twilt, M., & Benseler, S. M. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.197 · Cited by 75
Anti–NMDA-Receptor Encephalitis and Other Synaptic Autoimmune Disorders
Rosenfeld, M. R., & Dalmau, J. O. (2011) · Current Treatment Options in Neurology · doi:10.1007/s11940-011-0116-y · Cited by 75
Self-citationSarkis, R. A., Coffey, M. J., Cooper, J. J., Hassan, I., & Lennox, B. (2018) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.18010005 · Cited by 75
Gitiaux, C., Simonnet, H., Eisermann, M., Leunen, D., Dulac, O., Nabbout, R., Chevignard, M., Honnorat, J., Gataullina, S., Musset, L., et al. (2013) · Clinical Neurophysiology · doi:10.1016/j.clinph.2013.05.023 · Cited by 74
Wu, C., Wu, J., & Chen, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010911 · Cited by 74
Paraneoplastic Neurologic Syndromes
Rosenfeld, M. R., & Dalmau, J. O. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.04.015 · Cited by 74
Self-citationMaeder‐Ingvar, M., Prior, J. O., Irani, S. R., Rey, V., Vincent, A. C., & Rossetti, A. O. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.198697 · Cited by 74
Long-Term Cognitive Outcomes in Patients with Autoimmune Encephalitis
Hébert, J., Day, G. S., Steriade, C., Wennberg, R. A., & Tang‐Wai, D. F. (2018) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2018.33 · Cited by 74
Autoimmune encephalitis: a case series and comprehensive review of the literature
Wingfield, T., McHugh, C., Vas, A. L., Richardson, A. M. T., Wilkins, E., Bonington, A., & Varma, A. R. (2011) · QJM · doi:10.1093/qjmed/hcr111 · Cited by 73
The immunobiology of autoimmune encephalitides
Alexopoulos, H., & Dalakas, M. C. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102339 · Cited by 73
Geoffroy, C., Paoletti, P., & Mony, L. (2021) · The Journal of Physiology · doi:10.1113/jp280875 · Cited by 73
CSF Findings in Acute NMDAR and LGI1 Antibody–Associated Autoimmune Encephalitis
Dürr, M., Nissen, G., Sühs, K., Schwenkenbecher, P., Geis, C., Ringelstein, M., Hartung, H., Friese, M. A., Kaufmann, M., Malter, M. P., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001086 · Cited by 73
Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations
Kunchok, A. C., McKeon, A. B., Ζεκερίδου, Α., Flanagan, E. P., Dubey, D., Lennon, V. A., Klein, C. J., Mills, J. R., & Pittock, S. J. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.07.023 · Cited by 73
Goldberg, E. M., Titulaer, M. J., de Blank, P. M. K., Sievert, A. J., & Ryan, N. R. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.10.002 · Cited by 73
Anti-NMDAR autoimmune encephalitis
Miya, K., Takahashi, Y., & Mori, H. (2013) · Brain and Development · doi:10.1016/j.braindev.2013.10.005 · Cited by 73
Recognizing Autoimmune-Mediated Encephalitis in the Differential Diagnosis of Limbic Disorders
da Rocha, A. J., Nunes, R. H., Maia, A. C. M., & do Amaral, L. L. F. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4408 · Cited by 73
Autoimmune encephalitis in psychiatric institutions: current perspectives
Bost, C., Pascual, O., & Honnorat, J. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s82380 · Cited by 73
Immuno-psychiatry: an agenda for clinical practice and innovative research
Leboyer, M., Berk, M., Yolken, R. H., Tamouza, R., Kupfer, D. J., & Groc, L. (2016) · BMC Medicine · doi:10.1186/s12916-016-0712-5 · Cited by 74
Pollak, T. A., Beck, K., Irani, S. R., Howes, O. D., David, A. S., & McGuire, P. K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4156-y · Cited by 72
Autoimmunity to the Sodium-Level Sensor in the Brain Causes Essential Hypernatremia
Hiyama, T. Y., Matsuda, S., Fujikawa, A., Matsumoto, M., Watanabe, E., Kajiwara, H., Niimura, F., & Noda, M. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.017 · Cited by 72
Which antibody and which cancer in which paraneoplastic syndromes?
Gozzard, P., & Maddison, P. (2010) · Practical Neurology · doi:10.1136/jnnp.2010.224105 · Cited by 72
Pillai, S. C., Mohammad, S. S., Hacohen, Y., Tantsis, E. M., Prelog, K., Barnes, E. H., Gill, D. S., Lim, M. J., Brilot, F., Vincent, A. C., et al. (2015) · Epilepsia · doi:10.1111/epi.13253 · Cited by 72
Obi-Nagata, K., Temma, Y., & Hayashi‐Takagi, A. (2019) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.95.014 · Cited by 72
The immunobiology of herpes simplex virus encephalitis and post-viral autoimmunity
Cleaver, J., Jeffery, K. J., Klenerman, P., Lim, M. J., Handunnetthi, L., Irani, S. R., & Handel, A. E. (2023) · Brain · doi:10.1093/brain/awad419 · Cited by 74
Metadata
- Authors
- Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R.
- Affiliations
- University of Pennsylvania (US)
- Lankenau Institute for Medical Research (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Dalmau, Josep
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2008-12
- Volume
- 7
- Issue
- 12
- Pages
- 1091-1098
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC2607118
- OpenAlex
- W2146199022
- Semantic Scholar
- dd855374110d7c7789974ad4472f335d53b94cd9
- Cited by
- 3,488
- References
- 35
- Citations by year
- 2026: 117 · 2025: 130 · 2024: 170 · 2023: 140 · 2022: 198 · 2021: 239 · 2020: 233 · 2019: 525 · 2018: 213 · 2017: 207 · 2016: 227 · 2015: 196 · 2014: 182 · 2013: 196 · 2012: 169
- FWCI
- 72.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (F31MH083395, R56MH057683, R01MH057683, R21 MH057683)
- National Cancer Institute (R01CA089054, R56CA089054, R01CA107192)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Clinical Neurology › Myasthenia Gravis and Thymoma
- Keywords
- anti-NMDA receptor encephalitis, NMDA receptor antibodies, autoimmune encephalitis, ovarian teratoma, psychiatric symptoms, seizures, dyskinesia, autonomic instability, hypoventilation, antibody epitopes, cancer immunotherapy
- MeSH terms
- Adolescent, Adult, Aged, Animals, Epitopes, Autoantibodies, Autoantigens, Brain, Cell Line, Cells, Cultured, Child, Child, Preschool, Encephalitis, Epilepsy, Female, Humans, Male, Middle Aged, Ovarian Neoplasms, Teratoma, Receptors, N-Methyl-D-Aspartate, Neurocognitive Disorders, Autoimmune Diseases of the Nervous System, Paraneoplastic Syndromes, Nervous System, Protein Subunits, Rats, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
